Howell Nicholas, Sierro Frederic, Jarrah Raya, Dobie Christopher, Bevitt Joseph J, Garbe Ulf, Jakubowski Klaudiusz, Safavi-Naeini Mitra
Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW, Australia.
University of Wollongong, Wollongong, NSW, Australia.
Sci Rep. 2025 May 22;15(1):17786. doi: 10.1038/s41598-025-02382-4.
Neutron Capture Therapy (NCT) for cancer treatment is experiencing renewed interest due to advancements in accelerator-based neutron beams, treatment planning software, and patient positioning devices. This study presents the adaptation of an existing neutron radiography beamline (Dingo), at the OPAL research nuclear reactor, for radiobiological research and novel neutron capture agent development. Human glioblastoma cell cultures were irradiated for up to 10 min with a flux of 2.57 × 10 n/cm s (± 2.73 × 10) and the resulting impact was quantified by assessing DNA damage by both immunocytochemistry and flow cytometry. This low cost methodology extends the capability of an existing beamline to allow the development of novel neutron capture agents and study of neutron radiobiological mechanisms. Increasing availability of neutron sources for biological study in this fashion will accelerate the development of NCT for disease specific clinical application.
由于基于加速器的中子束、治疗计划软件和患者定位设备的进步,用于癌症治疗的中子俘获疗法(NCT)正重新引起人们的兴趣。本研究介绍了对OPAL研究核反应堆现有的中子照相束线(Dingo)进行改造,用于放射生物学研究和新型中子俘获剂开发。用人胶质母细胞瘤细胞培养物,以2.57×10⁹n/cm²·s(±2.73×10⁹)的通量照射长达10分钟,并通过免疫细胞化学和流式细胞术评估DNA损伤来量化所产生的影响。这种低成本方法扩展了现有束线的能力,以允许开发新型中子俘获剂并研究中子放射生物学机制。以这种方式增加用于生物学研究的中子源的可用性,将加速NCT针对特定疾病临床应用的开发。